PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

JOURNAL OF CLINICAL ONCOLOGY

AMER SOC CLINICAL ONCOLOGY

1. National Institute for Health Research [06/303/98] Funding Source: researchfish